Growth hormone axis
IGF-1 LR3
Long R3 IGF-1 · engineered · IGF-1 analog
An engineered, long-acting version of IGF-1 aimed at systemic muscle and tissue growth — potent, WADA-banned, and carries real, well-documented hypoglycaemia risk.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to resist the body's normal binding proteins so it stays active in the bloodstream far longer than natural IGF-1. This makes it considerably more potent — and less forgiving — than the natural hormone.
This is one of the few peptides in this library where the safety risk is not just theoretical: IGF-1 has real, well-established blood-sugar-lowering effects, and case reports of dangerous hypoglycaemia with LR3 use exist. It is not a compound to treat casually.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Drives systemic muscle and tissue growth”
Consistent with IGF-1's known biology; controlled human outcome trials at community doses don't exist.
Claim-level citation mapping is in progress.
“Well tolerated at typical community doses”
Contradicted by documented hypoglycaemia case reports — this claim understates a real risk.
Claim-level citation mapping is in progress.
“More effective than natural GH-driven IGF-1 production”
A community belief, not something tested head-to-head in controlled human trials.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not a licensed medicine in the UK; a research chemical only, banned in sport under WADA. No legal route for human-use sale, and it carries genuine, well-documented safety risk (hypoglycaemia) beyond most peptides on this site.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Regarded within the community itself as one of the higher-risk, 'advanced-only' compounds. Hypoglycaemia risk is one of the few safety issues discussed as seriously in forums as it is in the clinical literature.
Where they’re talking
- r/PeptidesHypoglycaemia and dosing-caution threads are common.
- Bodybuilding forumsWidely flagged as not for beginners.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency